{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:02:27Z","timestamp":1761058947387},"reference-count":13,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:p><jats:bold>Objective:\u2002<\/jats:bold> We report a patient who experienced delusional symptoms during gradual discontinuation of low\u2010dose venlafaxine and required antipsychotic treatment.<\/jats:p><jats:p><jats:bold>Method:\u2002<\/jats:bold> Case report.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> A 31\u2010year\u2010old woman with major depression had been treated abroad with venlafaxine before returning to Japan. Since venlafaxine is unavailable here, we supplemented her regular venlafaxine dosage of 37.5\u2003mg\/day with clomipramine 20\u2003mg\/day. After 5\u2003weeks we reduced venlafaxine to 18.75\u2003mg\/day and uptitrated clomipramine to 40\u2003mg\/day. Four days later she developed delusions of reference, palpitations and nausea. Clomipramine was increased to 60\u2003mg\/day, and her symptoms subsided. Eight weeks later her supply of venlafaxine ran out, and within 4\u2003days her condition deteriorated into more severe symptoms that required 4\u2003months\u2019 antipsychotic treatment.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> We speculate that her symptoms were discontinuation syndrome, including psychotic symptoms and physical symptoms, caused by (i) venlafaxine\u2010clomipramine interaction and\/or (ii) the serotonin reuptake inhibitor\u2010like effects of low\u2010dose venlafaxine.<\/jats:p>","DOI":"10.1111\/j.1600-0447.2009.01433.x","type":"journal-article","created":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T08:29:54Z","timestamp":1246436994000},"page":"329-331","source":"Crossref","is-referenced-by-count":7,"title":["Symptoms of delusion: the effects of discontinuation of low\u2010dose venlafaxine"],"prefix":"10.1111","volume":"120","author":[{"given":"M.","family":"Koga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Kodaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,10]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"EFFEXOR\u00ae Wyeth Pharmaceuticals website. Available athttp:\/\/www.wyeth.com\/content\/showlabeling.asp?id=99(accessed on April 5 2009)"},{"key":"e_1_2_6_3_2","unstructured":"Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants. Available athttp:\/\/www.mhra.gov.uk\/home\/groups\/pl\u2010p\/documents\/drugsafetymessage\/con019472.pdf(accessed on April 5 2009)"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.174.4.297"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1163\/1569391041501906"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199912030-00001"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.3.311"},{"key":"e_1_2_6_8_2","first-page":"285","article-title":"Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine or imipramine: initial findings","volume":"61","author":"Gomez JM","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(97)83303-2"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.12.1652a"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.3109\/00048679809062742"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145703003274"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900019726"},{"issue":"4","key":"e_1_2_6_14_2","first-page":"8","article-title":"Physiologic mechanisms underlying the antidepressant discontinuation syndrome","volume":"67","author":"Blier P","year":"1996","journal-title":"J Clin Psychiatry"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.2009.01433.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.2009.01433.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T13:13:07Z","timestamp":1697375587000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.2009.01433.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,10]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1600-0447.2009.01433.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.2009.01433.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,10]]}}}